Is Halozyme Therapeutics (HALO) A Good Long-Term Investment?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, its Investor Class fund ARTSX returned -21.52%, Advisor Class fund APDSX posted a return of -21.48%, and Institutional Class fund APHSX returned -21.47%, compared to a return of -19.25% for the Russell 2000 Growth Index. In addition, please check the fund’s top five holdings to know its best picks in 2022.

In the second quarter 2022 investor letter, Artisan Partners discussed stocks like Halozyme Therapeutics, Inc. (NASDAQ:HALO). Based in San Diego, California, Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharma technology company. On September 27, 2022, Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock closed at $38.64 per share. One-month return of Halozyme Therapeutics, Inc. (NASDAQ:HALO) was -5.13% and its shares lost 2.55% of their value over the last 52 weeks. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $5.382 billion.

Here is what Artisan Partners specifically said about Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Q2 2022 investor letter:

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biotechnology firm with a unique technology platform enabling the conversion of intravenous (IV) formulated biologic and small molecule drugs to a subcutaneous (SC) form. Pharmaceutical companies license this technology to optimize their flagship therapies, generating predictable and durable royalties for Halozyme. The company has a robust pipeline of 16 products and over 10 companies leveraging its ENHANZE® platform including a partnership with Argenx (another top 10 holding) for a subcutaneous format of efgartigimod which could obtain approval in 2023. Today, Halozyme has five royalty products. Over the next five years, we believe the number of new royalty generating products could triple.”

Source:unsplash

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the second quarter which was 21 in the previous quarter.

We discussed Halozyme Therapeutics, Inc. (NASDAQ:HALO) in another article and shared Bernzott Capital Advisors’ views on the company. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Disclosure: None. This article is originally published at Insider Monkey.